GLP-1 medications — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed weight and diabetes care, and their use is expanding quickly. They work largely by slowing stomach emptying and reducing appetite, so people feel full sooner and eat considerably less. That appetite reduction is the whole point, and it's effective. But it also reshapes the nutrition picture: when total intake drops by a quarter to a third or more, what you eat matters far more than it used to.
The central nutrition challenge on a GLP-1 isn't eating less; the medication handles that. It's making sure the smaller amount you do eat protects your muscle, covers your nutrient needs, and doesn't leave you depleted. Without attention to this, a meaningful share of weight lost can come from muscle rather than fat, and nutrient gaps can develop. The encouraging news is that these risks are largely preventable, and dietitians, though still underused in this setting, are central to getting it right.
This article reviews how GLP-1 medications affect eating, why protein and muscle are the priority, how to manage side effects, how to avoid nutrient deficiencies, and how nutrition supports lasting results.